

WATSON PHARMACEUTICALS INC  
Form 8-K  
November 30, 2004

**UNITED STATES**  
**SECURITIES AND EXCHANGE COMMISSION**

Washington, D.C. 20549

**FORM 8-K**

**CURRENT REPORT**

**Pursuant To Section 13 or 15(d) Of the Securities and Exchange Act Of 1934**

**November 30, 2004**  
Date of Report (Date of earliest event reported)

**WATSON PHARMACEUTICALS, INC.**

(Exact name of registrant as specified in its charter)

**Nevada**  
(State or other Jurisdiction  
of Incorporation)

**0-20045**  
(Commission File Number)

**95-3872914**  
(IRS Employer  
Identification Number)

**311 Bonnie Circle**  
**Corona, California**  
(Address of principal executive offices)

**92880**  
(Zip Code)

**(951) 493-5300**  
(Registrant's telephone number, including area code)

**N/A**  
(Former Name or Former Address, if Changed Since Last Report)

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:

- Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)
- Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)

CURRENT REPORT

Edgar Filing: WATSON PHARMACEUTICALS INC - Form 8-K

o Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))

o Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))

---

**Item 5.02** Department of Directors or Principal Officers; Election of Directors;  
Appointment of Principal Officers.

Effective November 30, 2004, Allen Chao, Ph.D. was appointed to fill the office of President of Watson Pharmaceuticals, Inc. (the "Company"). The appointment was made to fill the vacancy resulting from the recent departure of Joseph C. Papa, the Company's former President and Chief Operating Officer. Dr. Chao also serves as Chairman of the Board and Chief Executive Officer of the Company.

**SIGNATURES**

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

Dated: November 30, 2004.

WATSON PHARMACEUTICALS, INC.

By: /s/David A. Buchen

David A. Buchen

Senior Vice President, General Counsel

and Secretary